Oral drug trial aims to control blood disorder with fewer side effects
NCT ID NCT03502668
Summary
This study tested different low-dose schedules of an oral drug called ASTX727 for adults with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder that affects blood cell production. The main goals were to find a dose and schedule that is safe and effective at improving patients' blood counts and reducing their need for transfusions. Researchers enrolled 160 participants to compare how well the different treatment plans worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Az St-Jan Brugge-Oostende A.V.
Bruges, Belgium
-
BRCR Medical Center Inc.
Plantation, Florida, 33324, United States
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Univeristario y Politecnico La Fe Servicio de Hematologia
Valencia, 46026, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, Spain
-
Indiana University Health Hospital - Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Institut Català d'Oncologia Badalona Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
London Regional Cancer Center
London, Ontario, N6A 5W9, Canada
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Moffitt Cancer Center Site#507
Tampa, Florida, 33612, United States
-
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)
Bethesda, Maryland, 20817, United States
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universita degli Studi di Firenze
Florence, Italy
-
Universitaetsklinikum Freiburg Site#703
Freiburg im Breisgau, 79106, Germany
-
University of Alberta Hospital - Hematology Research
Edmonton, T6G 2B7, Canada
-
University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Kansas Clinical Research Center
Westwood, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Universitätsklinikum Halle
Halle, 06120, Germany
-
Vanderbilt University Medical Center - Hematology-Oncology
Nashville, Tennessee, 37232, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
-
ZNA - Campus Middelheim
Antwerp, Belgium
Conditions
Explore the condition pages connected to this study.